New combo aims to bridge blood cancer patients to Life-Saving transplant
NCT ID NCT07148947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding the drug pacritinib to standard treatments (azacitidine or decitabine) can help more people with advanced myeloproliferative neoplasms (MPN) get a stem cell transplant. The study will enroll 27 adults whose MPN has progressed to a more aggressive phase. The goal is to see if the combination can control the disease long enough to allow for a transplant, which may improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pacritinib (a targeted cancer drug) combined with azacitidine or decitabine (chemotherapy-like drugs)
- What this could lead to
- If successful, this approach could help more people with advanced myeloproliferative neoplasms become eligible for a potentially life-extending stem cell transplant.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply broadly. The combination therapy may cause side effects or fail to improve transplant rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.